表紙
市場調査レポート

骨髄異形成症候群:パイプライン分析

Myelodysplastic Syndrome - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 229721
出版日 ページ情報 英文 784 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
骨髄異形成症候群:パイプライン分析 Myelodysplastic Syndrome - Pipeline Review, H1 2016
出版日: 2016年05月25日 ページ情報: 英文 784 Pages
概要

骨髄異形成症候群(MDS)とは、骨髄およびそこで生成される血液細胞に発生する障害の一つです。その初期段階では、徴候・症状が現れることはほとんどありません。女症状として、倦怠感や息切れ、貧血に伴う顔面の異常な蒼白、容易かつ異常なあざ・出血、感染症の頻繁な発症などが挙げられます。

当レポートでは、世界各国での骨髄異形成症候群治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

骨髄異形成症候群の概要

治療薬の開発

  • 骨髄異形成症候群向けパイプライン製品:概要
  • 骨髄異形成症候群向けパイプライン製品:比較分析

各企業で開発中の骨髄異形成症候群治療薬

大学/研究機関で研究中の骨髄異形成症候群治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

骨髄異形成症候群治療薬:開発中の製品の一覧(企業別)

骨髄異形成症候群治療薬:研究中の製品の一覧(大学/研究機関別)

骨髄異形成症候群治療薬の開発に従事している企業

骨髄異形成症候群:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

骨髄異形成症候群治療薬:パイプライン製品の最新動向

骨髄異形成症候群治療薬:開発が休止状態の製品

骨髄異形成症候群治療薬:開発が中止された製品

骨髄異形成症候群関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7984IDB

Summary

Global Markets Direct's, 'Myelodysplastic Syndrome - Pipeline Review, H1 2016', provides an overview of the Myelodysplastic Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome
  • The report reviews pipeline therapeutics for Myelodysplastic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Myelodysplastic Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Myelodysplastic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Myelodysplastic Syndrome Overview
  • Therapeutics Development
  • Myelodysplastic Syndrome - Therapeutics under Development by Companies
  • Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes
  • Myelodysplastic Syndrome - Pipeline Products Glance
  • Myelodysplastic Syndrome - Products under Development by Companies
  • Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes
  • Myelodysplastic Syndrome - Companies Involved in Therapeutics Development
  • Myelodysplastic Syndrome - Therapeutics Assessment
  • Drug Profiles
  • Myelodysplastic Syndrome - Recent Pipeline Updates
  • Myelodysplastic Syndrome - Dormant Projects
  • Myelodysplastic Syndrome - Discontinued Products
  • Myelodysplastic Syndrome - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Myelodysplastic Syndrome, H1 2016
  • Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Myelodysplastic Syndrome - Pipeline by 4SC AG, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Acceleron Pharma, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Altor BioScience Corporation, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Amgen Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Apogenix GmbH, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Arog Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Atara Biotherapeutics, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by BioLineRx, Ltd., H1 2016
  • Myelodysplastic Syndrome - Pipeline by BioLite, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Boston Biomedical, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Cantex Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Celator Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Celgene Corporation, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Celyad SA, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by CrystalGenomics, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by CTI BioPharma Corp., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Myelodysplastic Syndrome - Pipeline by DiNonA Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Eisai Co., Ltd., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Eleos Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Eli Lilly and Company, H1 2016
  • Myelodysplastic Syndrome - Pipeline by EpiZyme, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Myelodysplastic Syndrome - Pipeline by FORMA Therapeutics, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Fujifilm Corporation, H1 2016
  • Myelodysplastic Syndrome - Pipeline by H3 Biomedicine Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by IGF Oncology, LLC., H1 2016
  • Myelodysplastic Syndrome - Pipeline by ImmunoGen, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Incyte Corporation, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Johnson & Johnson, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Juno Therapeutics Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corporation, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Kainos Medicine, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Kiadis Pharma B.V., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Myelodysplastic Syndrome - Pipeline by La Jolla Pharmaceutical Company, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by MacroGenics, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by medac GmbH, H1 2016
  • Myelodysplastic Syndrome - Pipeline by MedImmune, LLC, H1 2016
  • Myelodysplastic Syndrome - Pipeline by MEI Pharma, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Merck & Co., Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Merus B.V., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Mirati Therapeutics Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Mirna Therapeutics, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Nemucore Medical Innovations, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Novartis AG, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Onconova Therapeutics, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Opsona Therapeutics Limited, H1 2016
  • Myelodysplastic Syndrome - Pipeline by OXiGENE, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Pfizer Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Pharma Mar, S.A., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Plexxikon Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Polyphor Ltd., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Regen BioPharma, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Rich Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Seattle Genetics, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Stemline Therapeutics, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Synta Pharmaceuticals Corp., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Targazyme, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by TetraLogic Pharmaceuticals, H1 2016
  • Myelodysplastic Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016
  • Myelodysplastic Syndrome - Pipeline by Trillium Therapeutics Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Myelodysplastic Syndrome Therapeutics - Recent Pipeline Updates, H1 2016
  • Myelodysplastic Syndrome - Dormant Projects, H1 2016
  • Myelodysplastic Syndrome - Dormant Projects (Contd..1), H1 2016
  • Myelodysplastic Syndrome - Dormant Projects (Contd..2), H1 2016
  • Myelodysplastic Syndrome - Dormant Projects (Contd..3), H1 2016
  • Myelodysplastic Syndrome - Dormant Projects (Contd..4), H1 2016
  • Myelodysplastic Syndrome - Dormant Projects (Contd..5), H1 2016
  • Myelodysplastic Syndrome - Discontinued Products, H1 2016
  • Myelodysplastic Syndrome - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Myelodysplastic Syndrome, H1 2016
  • Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top